Chest
-
Randomized Controlled Trial Multicenter Study
A randomized investigator-masked double-bind placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis.
Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports. The objective of this study was to evaluate the efficacy and safety of thalidomide in severe cutaneous sarcoidosis. ⋯ At a dose of 100 mg daily for 3 months, our results do not encourage thalidomide use in cutaneous sarcoidosis.